HY-100013A1-10mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
HY-100013A1-25mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
HY-100013A1-5mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
HY-100013A1-50mg
|
MedChemexpress LLC
|
(1R,2R)-2-PCCA (hydrochloride) [CAS 1609563-71-4]
|
|
Neuroscience-Neuromodulation
|
|
HY-100131-10mg
|
MedChemexpress LLC
|
GSK481 [CAS 1622849-58-4]
|
|
COVID-19-immunoregulation
|
|
HY-100131-100mg
|
MedChemexpress LLC
|
GSK481 [CAS 1622849-58-4]
|
|
COVID-19-immunoregulation
|
|
HY-100131-2mg
|
MedChemexpress LLC
|
GSK481 [CAS 1622849-58-4]
|
|
COVID-19-immunoregulation
|
|
HY-100131-5mg
|
MedChemexpress LLC
|
GSK481 [CAS 1622849-58-4]
|
|
COVID-19-immunoregulation
|
|
HY-100131-50mg
|
MedChemexpress LLC
|
GSK481 [CAS 1622849-58-4]
|
|
COVID-19-immunoregulation
|
|
HY-100224-10mg
|
MedChemexpress LLC
|
SANT-1 [CAS 304909-07-7]
|
|
Cancer-programmed cell death
|
|
HY-100224-100mg
|
MedChemexpress LLC
|
SANT-1 [CAS 304909-07-7]
|
|
Cancer-programmed cell death
|
|
HY-100224-5mg
|
MedChemexpress LLC
|
SANT-1 [CAS 304909-07-7]
|
|
Cancer-programmed cell death
|
|
HY-100224-50mg
|
MedChemexpress LLC
|
SANT-1 [CAS 304909-07-7]
|
|
Cancer-programmed cell death
|
|
HY-10037-10mg
|
MedChemexpress LLC
|
Quiflapon [CAS 136668-42-3]
|
|
COVID-19-immunoregulation
|
|
HY-10037-100mg
|
MedChemexpress LLC
|
Quiflapon [CAS 136668-42-3]
|
|
COVID-19-immunoregulation
|
|
HY-10037-5mg
|
MedChemexpress LLC
|
Quiflapon [CAS 136668-42-3]
|
|
COVID-19-immunoregulation
|
|
HY-10037-50mg
|
MedChemexpress LLC
|
Quiflapon [CAS 136668-42-3]
|
|
COVID-19-immunoregulation
|
|
HY-100383-10mg
|
MedChemexpress LLC
|
BH3I-1 [CAS 300817-68-9]
|
|
Cancer-programmed cell death
|
|
HY-100383-100mg
|
MedChemexpress LLC
|
BH3I-1 [CAS 300817-68-9]
|
|
Cancer-programmed cell death
|
|
HY-100383-25mg
|
MedChemexpress LLC
|
BH3I-1 [CAS 300817-68-9]
|
|
Cancer-programmed cell death
|
|
HY-100383-5mg
|
MedChemexpress LLC
|
BH3I-1 [CAS 300817-68-9]
|
|
Cancer-programmed cell death
|
|
HY-100383-50mg
|
MedChemexpress LLC
|
BH3I-1 [CAS 300817-68-9]
|
|
Cancer-programmed cell death
|
|
HY-100443A-1mg
|
MedChemexpress LLC
|
trans-PX20606 [CAS 1268244-85-4]
|
|
Metabolism-sugar/lipid metabolism
|
|
HY-100443A-2mg
|
MedChemexpress LLC
|
trans-PX20606 [CAS 1268244-85-4]
|
|
Metabolism-sugar/lipid metabolism
|
|
HY-100443B-1mg
|
MedChemexpress LLC
|
(-)-PX20606 (trans isomer) [CAS 1268244-88-7]
|
|
Metabolism-sugar/lipid metabolism
|
|